Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature

Table 3

Transplant outcomes.

Reference	Engraf. failure	Med. days to neut./PLT eng.	aGVHD; II–IV/III-IV	cGVHD	NRM	Relapse	EFS/PFS	OS
O’Donnell et al., 2002 [24]	20%; Cohort 2	15/14	46%/23%	1/10 limited	1/10 died of GVHD	4/10 cohort 2 relapsed	At med. f/u 6 mo. 5/10 in CR	At med. f/u 6 mo. 6/10 (cohort 2) alive
Luznik et al., 2008 [25]	13%	15/24	34%/6%	Ext. 5% in 2 doses of CY versus 25% in one dose of Cy	1 y 15%	1 y 51%	2 y EFS 26%	2 y 36%
Symons et al., 2011 [26]	4%	25/32	14%/7.3%	13%	100 D 12%	1 y 66% poor risk; 1 y 13% in CR	1 y 23.5%	1 y 40%
Brunstein et al., 2011 [27]	2%	16/24	32%/0	1 y 13%	1 y 7%	1 y 45%	1 y PFS 48%	1 y 62%
Pingali et al., 2014 [28]	4.7%	18/NA	32.6%/7.8%	21.3%/Ext. 10%	25%	3 y 30.1%	3 y PFS 42.3%	1 y OS 64%; Median OS for 1st SCT 25.6 mo.; 2nd SCT 6.5 mo.
Solomon et al., 2012 [29]	0%	16/27	30%/10%	35%/severe 5%	1 y 10%	1 y 40%	1 y DFS 50%	1 y 69%
Raiola et al., 2013 [30]	6%	18/23	12%/6%	26%/Ext. 0	6 mo. 18%	18 mo. 22%	DFS 18 mo. 51%	18 mo. 62%
Raj et al., 2014 [31]	4%	17/21	II 35%; III 8%; IV 0%	18% @ 2 y; 2 severe cases	1 y 17%	2 y 28%	2 y 51%	2 y 48%
Bhamidipati et al., 2014 [32]	6%	15/18	All grades 53%/17%	8% @ 2 y; Ext. only in 1 patient	1 y 17%	1 y 38%	1 y 53%	1 y 62%
Castagna et al., 2014 [33]	NA	BM 21/29	25%/3%	13%	2 y 19%	1 y 22%	2 y PFS 62%	2 y 68%
	NA	PB 20/27	33%/14%	13%		1 y 12%
Solomon et al., 2015 [34]	0	16/25	43%/23%	56%/Ext. 10%	2 y 3%	2 y 24%	2 y DFS 73%	2 y 78%
Bradstock et al., 2015 [35]	0	15/18	I–III 55.1%; No IV	28.6%	6 mo. 0	2 y 43.9%	2 y EFS 44.9%	2 y 52.7%
	13%	16/24	I–III 48.5%; No IV	32.3%	6 mo. 0	2 y 23.5%	2 y EFS; 63.6%	2 y 83.4%
Gayoso et al., 2013 [36]	NA	18/27	33%/14%	24%/Ext. 12%	6 mo. 19%	NA	1 y EFS; 48%	1 y 60%
Sugita et al., 2015 [37]	13%; (0 in no h/o SCT; 31% in h/o SCT)	19/35	23%/3%	15%/none severe	1 y 23%	1 y 45%	1 y DFS; 34%	1 y 45%

aGVHD, acute graft versus host disease; cGVHD, chronic graft versus host disease; CR, complete remission; Cy, cyclophosphamide; D, day; DFS, disease-free survival; Engraf., engraftment; EFS, event-free survival; Ext., extensive; mo., months; neut., neutrophils; NRM, nonrelapse mortality; OS, overall survival; PFS, progression-free survival; PLT, platelets; y, year.